Clinigen To Test U.K. Investors' Appetite For A Pharma Company IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
A U.K. supplier of drugs for clinical trials and fledgling specialty pharma company, Clinigen Group, has announced its intention to test U.K. investors' appetite for a pharmaceutical company IPO, with a listing and institutional fundraising on AIM, part of the London Stock Exchange.
You may also be interested in...
France's Adocia Completes 2012's First Euro Biotech IPO
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.